ing tumors thus increasing survival of treated mice. Cancer gene therapy trials involving IL-12 have until now relied on intradermal gene transfer [10] , gene gun method [11, 12] or adenoviruses [13, 14] . The choice of IL-12 is not accidental as its proinflammatory and immunostimulatory modes of action are well-known. IL-12 induces proliferation of several subpopulations of lymphocytes including T H1 cells, natural killer (NK) and lymphokineactivated killer (LAK) cells. IL-12 induces production of TNF-a and IFN-g [9] . IL-12 gene-based therapy appears to be a potentially safer alternative to systemic IL-12 protein-based therapy [15] .
MATERIALS AND METHODS
Plasmids. We used in our therapeutic experiments the pBCMGSNeo/mIL-12 plasmid containing sequences encoding both subunits of murine IL-12 (p35 and p40, separated by an IRES sequence), under the control of cytomegalovirus promoter (construct obtained from Dr. H. Yamamoto) [16] . As a control we used the pBCMGSNeo plasmid (obtained from Dr. H. Karasuyama from the Basel Institute of Immunology). In some experiments we used the pVR 1255 plasmid which encodes a luciferase reporter gene under the control of CMV promoter as well as a kanamycin resistance gene (obtained from Dr. R.H. Zaugg, Vical, San Diego, CA) [17] . For preparative plasmid DNA isolation from spheroplasts we followed the protocol of Wicks and coworkers [18] .
Cell lines and tissue culture. Renca cells (murine renal carcinoma line) and B16(F10) cells (murine melanoma line) were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco BRL). Cultures were kept at 37°C in 5% CO 2 incubator.
Cationic DNA carriers. As carriers of plasmid DNA we used cationic liposomes DDAB/DOPE [19] and DC-Chol/DOPE [20] . Liposomes were prepared at weight ratios of 0.6 : 1 (DDAB/DOPE) and 1 : 1 (DC-Chol/ DOPE). Liposome preparations (sonicated emulsions at 1 mg total lipids/ml H 2 O) were kept at 4°C and used within 2 weeks.
Animals. 6-8-week-old BALB/c and C57BL/6 mice were from our own animal facility. Mice had their left dorsal side shaved and were then inoculated subcutaneously with either Renca cells (5´10 5 
RESULTS

Transfer of naked plasmid DNA results in higher in vivo transfection level of neoplastic cells compared with lipoplexes
Ten mg of naked plasmid DNA (pVR 1255 containing the luciferase gene) as well as plasmid DNA complexed with cationic lipids DDAB/DOPE or DC-Chol/DOPE were transferred into growing Renca and B16(F10) tumors. Expression of the introduced luciferase gene in neoplastic cells transfected with naked plasmid DNA was one order of magnitude higher than in cells transfected by means of liposomal carriers (Table 1) .
Transgene expression duration and optimum amounts of DNA transferred into growing tumors
Our studies show that the most suitable solutions to carry out DNA transfer are: isotonic PBS (without Ca 2+ or Mg 2+ ), 15% mannitol containing heparin (2.5 unit/ml) in 0.9% NaCl, and Ringer's solution with 0.05% lactose. Transgene expression levels in neoplastic cells transformed using these solutions are similar (not shown). Different amounts of pVR 1255 DNA carrying the luciferase reporter gene were transferred into growing tumors. The highest transgene activity was observed when about 50 mg of DNA was used (Fig. 1A) . We also determined the duration of plasmid DNA expression in Renca tumor cells. The enzymatic activity of luciferase in neoplastic cells was determined during consecutive days of the experiment. Transgene expression persists for about 22 days. The maximum activity was detected after four days following DNA transfer (Fig. 1B) .
Amount of IL-12 in tumors
Amounts of IL-12 in transfected Renca tumor cells were determined in tumor lysates obtained following either single or fivefold administration of the transgene directly into a growing tumor. The amount of IL-12 following single DNA administration reached 800 pg/ mg protein while fivefold administration resulted in about 2000 pg/mg protein (Fig. 2) .
Effect of IL-12 therapeutic gene on survival of mice harboring Renca tumors
Syngenic BALB/c mice previously inoculated with Renca cells were then subjected to intratumoral injections of 50 mg pBCMG- SNeo/mIL-12 DNA which includes the IL-12 therapeutic gene. The therapy schemes were started either on day 3, day 7 or day 11 following inoculation of mice with cancer cells (Fig. 3) . Control animals were treated with an "empty" pBCMGSNeo vector (without the IL-12 gene). Therapy started on the third day gave a clear-cut therapeutic effect (100% cure rate). When the therapy was started on day 7 of the experiment its effectiveness decreased to 40% cure rate. If started on day 11, however, no therapeutic results were seen (i.e. the therapeutic effect was similar to that observed in mice receiving the "empty" vector without IL-12 gene).
The therapeutic effect, i.e. inhibition of tumor growth and lengthened survival of treated mice depends on time elapsed between inoculation of mice with cancer cells and beginning of treatment. In other words, smaller tumors respond to treatment better than larger ones.
DISCUSSION
Our experiments confirmed earlier reports about the feasibility of transferring naked DNA into neoplastic cells in vivo [8] . The level of luciferase gene expression in Renca and B16(F10) cells is higher in the case of direct intratumoral injection of plasmid DNA, compared with the use of liposomal carriers to transfer the DNA (Table 1 ). The maximum amount of DNA transferable via liposomes in a similar setup does not exceed 10 mg [22] . The feasibility of direct transfer of plasmid DNA into the tumor makes it possible to significantly increase the dose of therapeutic DNA. In our study we found that the optimum amount of naked plasmid DNA was about 50 mg (Fig. 1A) . The persistence of transgene expression in tumor cells depends on tumor type and ranges from about 1 week for B16(F10) cells (data not shown) to about 3 weeks for Renca cells (Fig. 1B) . It is likely a consequence of different tumor growth dynamics: faster-dividing B16(F10) cells can lose their transgene faster. On the basis of these results we carried out therapeutic experiments involving the transfer of the IL-12 gene. When this gene was administered directly into growing Renca tumors we observed an evident therapeutic effect. The sooner the treatment started the better its efficacy was (Fig. 3) . Presumably, cancer cells in large tumors grow at a rate vastly exceeding that of their depletion and/or the amount of IL-12 produced is not sufficient to generate the therapeutic effect (see [23] ). Only mice treated from the third day following inoculation with cancer cells could be cured with 100% efficiency, i.e. complete tumor regression could be seen (Fig. 3) .
So far, there have been no reports concerning direct transfer of naked plasmid DNA containing the IL-12 gene into growing tumors. The only report describing direct transfer of therapeutic plasmid DNA into growing tumors concerns the bax 2 and p53 genes [24] .
It seems that besides its simplicity, the therapy relying on direct transfer of plasmid DNA (carrying a therapeutic gene) into growing tumors in situ has some other advantages. The use of naked plasmid DNA allows the introduction of much larger doses of therapeutic DNA in comparison with lipoplex formulations. The amount of DNA complexed with liposomes is rather fixed and much lower ( [22] ). Furthermore, plasmid DNA is relatively straightforward to handle. Last but not least, it can be administered repeatedly.
According to Yang et al. [8] and Coll et al. [24] the fraction of tumor cells transfectable with naked DNA does not exceed 1%. Nonetheless, even with transfection efficiencies this low, a distinct therapeutic effect can be observed under certain conditions [24] . This coincides with increased IL-12 level following repeated direct intratumoral DNA injections (Fig. 2) . In our experiments the therapeutic effect of IL-12 may be additionally amplified thanks to short immunostimulatory sequences (called ISS and containing the CpG Vol. 47 Transfer of IL-12 389
Day of experiment % of mice surviving dinucleotide in a particular base context) within the ampR gene present in pBCMGSNeo [25, 26] . Unmethylated CpG sequences present in plasmid DNA may costimulate the activation of T H1 cells [27] . Experiments with naked DNA may be useful in preclinical investigations to test prospective gene therapy constructs (mainly those with immunomodulatory properties). In addition, its costs are lower than those incurred in implementing therapies based on viral, liposome or polypeptide carriers or therapies requiring sophisticated equipment (such as a gene gun).
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